Axsome Therapeutics, INC Form 4 insider transactions

Chief Commercial Officer Ari Maizel reports the acquisition of stock options, restricted stock units, and performance stock units in Axsome Therapeutics.

Hunter R. Murdock, General Counsel of Axsome Therapeutics, reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs).

Nick Pizzie, CFO of Axsome Therapeutics, reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs).

Chief Operating Officer of Axsome Therapeutics, Mark L. Jacobson, reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs).

CEO Herriot Tabuteau reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs) in Axsome Therapeutics.

Axsome Therapeutics' CFO, Nick Pizzie, exercised stock options and sold shares under a pre-approved 10b5-1 trading plan, completing the plan's transactions.

Director Mark Coleman exercised stock options in Axsome Therapeutics, acquiring shares while also holding a significant indirect ownership stake.

Axsome Therapeutics director Mark Coleman exercised stock options to acquire 33,410 shares of common stock at $5.94 per share.

Director Mark E. Saad of Axsome Therapeutics exercised stock options and sold shares on September 11, 2024, according to a Form 4 filing with the SEC.

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, exercised stock options and sold the resulting shares under a pre-approved 10b5-1 trading plan.

Director Susan Mahony acquired 5,799 stock options in Axsome Therapeutics on June 7, 2024, exercisable starting June 7, 2025.

Mark Coleman, a director at Axsome Therapeutics, reported the acquisition of stock options exercisable for 5,799 shares of common stock.

Director Roger Jeffs of Axsome Therapeutics acquired 5,799 stock options on June 7, 2024, exercisable starting June 7, 2025.

Director Mark E. Saad acquired stock options for 5,799 shares of Axsome Therapeutics, Inc. on June 7, 2024.

Mark Jacobson, Chief Operating Officer of Axsome Therapeutics, exercised stock options and sold a portion of the underlying shares to cover tax obligations.

Director Mark Coleman of Axsome Therapeutics sold shares of common stock on May 28 and May 29, 2024, under a pre-approved 10b5-1 trading plan.

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, exercised stock options and sold the resulting shares on April 1, 2024, according to a pre-approved 10b5-1 plan.

Director Roger Jeffs exercised stock options and sold shares of Axsome Therapeutics (AXSM) common stock on March 14-15, 2024, under a pre-approved 10b5-1 trading plan.

Director Roger Jeffs acquired 1,425 stock options in Axsome Therapeutics in lieu of cash compensation earned in 2023.

Director Mark E. Saad acquired 1,519 stock options in Axsome Therapeutics, Inc. in lieu of cash compensation earned in 2023.

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, reports acquisition of stock options and restricted stock units.

Axsome Therapeutics' CFO, Nick Pizzie, reported the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

CEO of Axsome Therapeutics, Herriot Tabuteau, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Director Susan Mahony acquired 191 stock options in Axsome Therapeutics in lieu of cash compensation on February 27, 2024.

Hunter R. Murdock, General Counsel of Axsome Therapeutics, reports the acquisition of stock options and restricted stock units.